Option Care Health, Inc.

NasdaqGS:OPCH Stock Report

Market Cap: US$3.4b

Option Care Health Valuation

Is OPCH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of OPCH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: OPCH ($21.35) is trading below our estimate of future cash flow value ($24.88)

Significantly Below Future Cash Flow Value: OPCH is trading below future cash flow value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for OPCH?

Key metric: As OPCH is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for OPCH. This is calculated by dividing OPCH's market cap by their current earnings.
What is OPCH's PE Ratio?
PE Ratio16.3x
EarningsUS$206.19m
Market CapUS$3.41b

Price to Earnings Ratio vs Peers

How does OPCH's PE Ratio compare to its peers?

The above table shows the PE ratio for OPCH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average104.7x
PRVA Privia Health Group
162.3x31.93%US$3.5b
CRVL CorVel
28.7xn/aUS$3.2b
LFST LifeStance Health Group
180.4x49.69%US$4.2b
GRDN Guardian Pharmacy Services
47.3x15.80%US$2.6b
OPCH Option Care Health
16.3x11.42%US$3.4b

Price-To-Earnings vs Peers: OPCH is good value based on its Price-To-Earnings Ratio (16.3x) compared to the peer average (104.7x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does OPCH's PE Ratio compare vs other companies in the US Healthcare Industry?

7 CompaniesPrice / EarningsEstimated GrowthMarket Cap
CYH Community Health Systems
0.9x-109.55%US$471.38m
IDXG Interpace Biosciences
1.9xn/aUS$41.55m
NIVF NewGenIvf Group
0.5xn/aUS$4.73m
RHEP Regional Health Properties
1.1xn/aUS$4.13m
OPCH 16.3xIndustry Avg. 25.0xNo. of Companies11PE020406080100+
7 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: OPCH is good value based on its Price-To-Earnings Ratio (16.3x) compared to the US Healthcare industry average (25x).

Price to Earnings Ratio vs Fair Ratio

What is OPCH's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

OPCH PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio16.3x
Fair PE Ratio23.6x

Price-To-Earnings vs Fair Ratio: OPCH is good value based on its Price-To-Earnings Ratio (16.3x) compared to the estimated Fair Price-To-Earnings Ratio (23.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst OPCH forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$21.35
US$28.58
+33.88%
17.11%US$39.00US$22.00n/a12
Jul ’27US$21.04
US$28.58
+35.85%
17.11%US$39.00US$22.00n/a12
Jun ’27US$20.46
US$29.18
+42.63%
15.99%US$39.00US$22.00n/a11
May ’27US$20.03
US$30.73
+53.41%
19.43%US$40.00US$22.00n/a11
Apr ’27US$26.49
US$40.09
+51.34%
5.77%US$45.00US$37.00n/a11
Mar ’27US$32.46
US$40.09
+23.51%
5.77%US$45.00US$37.00n/a11
Feb ’27US$34.00
US$39.82
+17.11%
6.41%US$45.00US$36.00n/a11
Jan ’27US$31.86
US$36.45
+14.42%
8.78%US$40.00US$30.00n/a11
Dec ’26US$30.94
US$35.30
+14.09%
10.37%US$40.00US$30.00n/a10
Nov ’26US$26.03
US$35.50
+36.38%
11.00%US$41.00US$30.00n/a10
Oct ’26US$27.24
US$38.78
+42.36%
4.98%US$41.00US$34.00n/a9
Sep ’26US$28.68
US$38.78
+35.21%
4.98%US$41.00US$34.00n/a9
Aug ’26US$28.26
US$38.78
+37.22%
4.98%US$41.00US$34.00n/a9
Jul ’26US$31.95
US$38.56
+20.67%
5.48%US$41.00US$34.00US$21.049
Jun ’26US$32.68
US$38.56
+17.98%
5.48%US$41.00US$34.00US$20.469
May ’26US$32.17
US$38.56
+19.85%
5.48%US$41.00US$34.00US$20.039
Apr ’26US$34.95
US$37.78
+8.09%
6.58%US$41.00US$33.00US$26.499
Mar ’26US$33.50
US$36.44
+8.79%
6.22%US$40.00US$33.00US$32.469
Feb ’26US$30.92
US$31.56
+2.06%
15.32%US$40.00US$25.00US$34.009
Jan ’26US$23.20
US$29.78
+28.35%
14.05%US$38.00US$25.00US$31.869
Dec ’25US$23.80
US$30.88
+29.73%
11.73%US$38.00US$26.00US$30.948
Nov ’25US$24.11
US$32.75
+35.84%
14.70%US$42.00US$26.00US$26.038
Oct ’25US$30.15
US$39.38
+30.60%
5.95%US$43.00US$36.00US$27.248
Sep ’25US$32.02
US$39.25
+22.58%
6.34%US$43.00US$36.00US$28.688
Aug ’25US$30.77
US$39.25
+27.56%
6.34%US$43.00US$36.00US$28.268
Jul ’25US$27.34
US$39.43
+44.22%
6.04%US$43.00US$36.00US$31.957
US$28.58
Fair Value
25.3% undervalued intrinsic discount
12
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/14 21:30
End of Day Share Price 2026/07/14 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Option Care Health, Inc. is covered by 15 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael PetuskyBarrington Research Associates, Inc.
Joanna Sylvia GajukBofA Global Research
Richard CloseCanaccord Genuity